ジェダイトメディスン

Jadeite Medicines Inc. was established for Japanese patients with its mission of developing and commercializing novel innovative medicines developed globally.

Jadeite Medicines Inc. aims to become the best partner for innovative companies around the world and to meet the unmet medical needs in Japan.

25th December 2024 Jadeite Medicines Receives Orphan Drug Designation with Odevixibat for Treatment of Alagille Syndrome (ALGS) from Ministry of Health, Labour and Welfare of Japan / 23th December 2024 Jadeite Medicines Completes Phase 3 Trial of Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) and Preparation of Dossier for New Drug Application (NDA) in Japan >>>Press Release
(Details here)